Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel

Esmaeli, Bita; Amin, Sapna; Valero, Vicente; Adinin, R.; Arbuckle, Rebecca; Banay, R.; Anh, Kim; Rivera, Edgardo

doi:10.1200/jco.2005.04.4453

Cited by 54 publications

(43 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excessive tearing interferes with daily life activities such as driving, reading, and visual tasks. The frequency and severity of epiphora increased with weekly administration of docetaxel compared with administration every 3 weeks [8]. In addition, ocular toxicity occurred in patients receiving a median or mean cumulative docetaxel dose of 300 or 400 mg/m 2 or a higher dose [9].…”

Section: Discussionmentioning

confidence: 99%

Epiphora in lung cancer patients receiving docetaxel: a case series

et al. 2014

View full text Add to dashboard Cite

BackgroundDocetaxel is a key antineoplastic drug for treatment of non-small cell lung cancer. Ocular adverse events of docetaxel include epiphora (excess tearing) and conjunctivitis. Epiphora has been reported to be associated with canalicular and nasolacrimal duct stenosis, but it is not necessarily caused by lacrimal duct obstruction.Case presentationWe encountered three Japanese non-small cell lung cancer patients who developed epiphora after the administration of docetaxel-based chemotherapy. One patient with lacrimal puncta stenosis showed improvement with probing and irrigation. The other two patients resolved following cessation of docetaxel or administration of artificial tears.ConclusionAs epiphora can interfere with activities of daily life and negatively affect quality of life, it is important for thoracic oncologists to be aware of this adverse event.

show abstract

Section: Discussionmentioning

confidence: 99%

Epiphora in lung cancer patients receiving docetaxel: a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Docetaxel can be present in tears,85 and it leads to epiphora mainly by causing canalicular stenosis in the lacrimal drainage apparatus 86. The severity and frequency of epiphora is less with the tri-weekly dosing schedule,87 but since published studies used the longer treatment regimens for metastaric BC,87–89 reported frequencies of epiphora (as high as ∼40% for tri-weekly treatments vs. ∼65% for weekly treatments)87 would overestimate the corresponding frequencies for early-stage (or shorter)89 treatment regimens. Based on our clinical experience (author SWL), about 1-2% of early-stage BC patients spontaneously report experiencing epiphora by the end of a 4-cycle TC regimen.…”

Section: Chemotherapeutic Agents Used Shortly After Bc Diagnosismentioning

confidence: 99%

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Eisner¹,

Luoh²

2011

Current Eye Research

View full text Add to dashboard Cite

This review concerns the effects on vision and the eye of medications prescribed at three phases of treatment for women with early-stage breast cancer (BC): (1) adjuvant cytotoxic chemotherapy, (2) adjuvant endocrine therapy, and (3) symptomatic relief. The most common side effects of cytotoxic chemotherapy are epiphora and ocular surface irritation, which can be caused by any of several different regimens. Most notably, the taxane docetaxel can lead to epiphora by inducing canalicular stenosis. The selective-estrogen-receptor-modulator (SERM) tamoxifen, long the gold-standard adjuvant-endocrine-therapy for women with hormone-receptor-positive BC, increases the risk of posterior subcapsular cataract. Tamoxifen also affects the optic nerve head more often than previously thought, apparently by causing subclinical swelling within the first 2 years of use for women older than ∼50 years. Tamoxifen retinopathy is rare, but it can cause foveal cystoid spaces that are revealed with spectral-domain optical coherence tomography (OCT) and that may increase the risk for macular holes. Tamoxifen often alters the perceived color of flashed lights detected via short-wavelength-sensitive (SWS) cone response isolated psychophysically; these altered perceptions may reflect a neural-response sluggishness that becomes evident at ∼2 years of use. The aromatase inhibitor (AI) anastrozole affects perception similarly, but in an age-dependent manner suggesting that the change of estrogen activity towards lower levels is more important than the low estrogen activity itself. Based on analysis of OCT retinal thickness data, it is likely that anastrozole increases the tractional force between the vitreous and retina. Consequently, AI users, myopic AI users particularly, might be at increased risk for traction-related vision loss. Because bisphosphonates are sometimes prescribed to redress AI-induced bone loss, clinicians should be aware of their potential to cause scleritis and uveitis occasionally. We conclude by suggesting some avenues for future research into the visual and ocular effects of AIs, particularly as relates to assessment of cognitive function.

show abstract

“…A paclitaxel-eluting stent was even used in prevention of human malignant biliary obstruction [19]. Nevertheless, it was reported that prolonged chemotherapeutic treatment with paclitaxel/docetaxel was associated with canalicular stenosis, pulmonary fibrosis or scleroderma-like changes, albeit in only a small fraction of the patients [20], [21], [22]. It should be indicated that the inhibition of tumor cell proliferation can be achieved by much higher dosages of paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel Inhibits Urethral Stricture Formation, an Initial Study in Rabbit Model

Chong

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

IntroductionUrethral stricture, a frequent source of lower urinary tract disorders in men, is still a difficult problem for urologists. Based the anti-restenosis effect of paclitaxel on coronary artery, the role of docetaxel, a semi-synthetic analogue of paclitaxel, in limiting urethral stricture formation was studied.MethodsForty adult New Zealand male rabbits were involved in this study, which were randomly assigned into 3 groups, namely a high dose docetaxel (DH, 0.1 mg/d), a low dose docetaxel (DL, 0.01 mg/d) and a control (C) group, with 16, 16, 8 rabbits in each group, respectively. All animals underwent a 10 mm-long circumferential electrocoagulation of the bulbar urethra with a 13Fr pediatric resectoscope. Drugs were given by urethral irrigation daily and continuous for 28 days. Stricture formation was assessed by retrograde urethrography and videourethroscopy. Urethra pathology was evaluated by hematoxylin and eosin staining and Sirius red staining.ResultsAt the end of this study, 15, 14 and 7 rabbits remained for evaluation in DH, DL and C group, respectively. Urethral diameters in DH, DL and C group were (7.17±1.63) mm, (6.55±0.62) mm, (3.23±1.36) mm, with a normal urethral diameter of (9.08±1.29) mm. Lumen reduction in DH, DL and C group were (36.93±11.58)%, (48.03±7.89)% and (84.66±14.95)%, respectively. Statistically difference could be found between every two groups (p<0.05) both in urethral diameters and in lumen reduction, except for compare of urethral diameters between DH and DL group. Histological examination confirmed mass fibrous tissue and collagen content at the stricture sit in C group, whereas less in docetaxel treated rabbits.ConclusionsDocetaxel could limit urethral stricture formation, which may be due to inhibition of fibrous tissue and collagen expression. Docetaxel may become a new choice in the prevention of urethral stricture formation.

show abstract

Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel

Abstract: Epiphora occurred in 64% of patients in the weekly group and in 39% of patients in the every-3-weeks group. Moderate or severe canalicular stenosis was seen in about one-third of patients in the weekly group and in none of the patients in the every-3-weeks group.

Cited by 54 publications

References 12 publications

Epiphora in lung cancer patients receiving docetaxel: a case series

Epiphora in lung cancer patients receiving docetaxel: a case series

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Docetaxel Inhibits Urethral Stricture Formation, an Initial Study in Rabbit Model

Contact Info

Product

Resources

About